BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34762160)

  • 21. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.
    Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2020 May; 36(5):941-949. PubMed ID: 32025869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
    Ryall S; Guzman M; Elbabaa SK; Luu B; Mack SC; Zapotocky M; Taylor MD; Hawkins C; Ramaswamy V
    Childs Nerv Syst; 2017 Jul; 33(7):1047-1051. PubMed ID: 28623522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
    Nobusawa S; Hirato J; Yokoo H
    Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
    Mack SC; Pajtler KW; Chavez L; Okonechnikov K; Bertrand KC; Wang X; Erkek S; Federation A; Song A; Lee C; Wang X; McDonald L; Morrow JJ; Saiakhova A; Sin-Chan P; Wu Q; Michaelraj KA; Miller TE; Hubert CG; Ryzhova M; Garzia L; Donovan L; Dombrowski S; Factor DC; Luu B; Valentim CLL; Gimple RC; Morton A; Kim L; Prager BC; Lee JJY; Wu X; Zuccaro J; Thompson Y; Holgado BL; Reimand J; Ke SQ; Tropper A; Lai S; Vijayarajah S; Doan S; Mahadev V; Miñan AF; Gröbner SN; Lienhard M; Zapatka M; Huang Z; Aldape KD; Carcaboso AM; Houghton PJ; Keir ST; Milde T; Witt H; Li Y; Li CJ; Bian XW; Jones DTW; Scott I; Singh SK; Huang A; Dirks PB; Bouffet E; Bradner JE; Ramaswamy V; Jabado N; Rutka JT; Northcott PA; Lupien M; Lichter P; Korshunov A; Scacheri PC; Pfister SM; Kool M; Taylor MD; Rich JN
    Nature; 2018 Jan; 553(7686):101-105. PubMed ID: 29258295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
    Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD
    J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYCN amplification drives an aggressive form of spinal ependymoma.
    Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
    Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
    Shu C; Wang Q; Yan X; Wang J
    Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
    Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
    Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Whitehouse JP; Hii H; Mayoh C; Wong M; Ajuyah P; Barahona P; Cui L; Dholaria H; White CL; Buntine MK; Byrne J; Rodrigues da Silva K; Howlett M; Girard EJ; Tsoli M; Ziegler DS; Dyke JM; Lee S; Ekert PG; Cowley MJ; Gottardo NG; Endersby R
    Front Oncol; 2023; 13():1123492. PubMed ID: 36937401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
    Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
    Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
    Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
    Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of copy number variants in the classification of intracranial ependymoma.
    Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
    Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Repurposing in Pediatric Brain Tumors: Posterior Fossa Ependymoma and Diffuse Midline Glioma under the Looking Glass.
    Servidei T; Sgambato A; Lucchetti D; Navarra P; Ruggiero A
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):77. PubMed ID: 37114548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.
    Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X
    J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
    Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
    de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
    J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.